Host John Russell, MD
Guest Philip Philip, MD, PhD, FACP
Guest Kurt Tauer, MD, FACP
Dr Philip and Dr. Tauer are paid consultants for Amgen
As the third most common cancer in the United States, metastatic colorectal cancer (mCRC) can be a frightening diagnosis for many men and women.1 For these patients, which factors impact first-line treatment decisions? Join Dr. John Russell as he hosts Dr. Philip Philip, medical oncologist and Professor at the Karmanos Cancer Institute, and Dr. Kurt Tauer, medical oncologist at the West Cancer Center and Associate Professor at the University of Tennessee Health Science Center, in a discussion about first-line treatment decisions and the real-world implications of PRIME, the phase 3 trial of Vectibix® + FOLFOX vs. FOLFOX alone in mCRC.
In this discussion, Drs. Philip and Tauer will review:
After listening to the discussion, view hypothetical patient profiles and learn if Vectibix® may be right for your patients with wild-type RAS mCRC. Visit Vectibix.com
FOLFOX = fluorouracil, leucovorin, and oxaliplatin; PRIME = Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy.
Vectibix® is indicated for the treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC):
Limitation of Use
Vectibix® is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.